Skip to content

Savara SVRA Debt-to-assets

Debt-to-assets at other companies

XER
Xeris Biopharma Holdings, Inc.XERS
0.7×-0.2×
Innoviva, Inc. logo
Innoviva, Inc.INVA
0.1×-0.2×
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
-0.4×
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
0.2×0.0×
Theravance Biopharma logo
Theravance BiopharmaTBPH
0.1×-0.1×
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
0.3×0.0×

Other financials

Income statement

See full
Revenue-
Operating income-$39.0M-37.1%
Net income-$37.3M-40.0%
EPS (diluted)-$0.15-25.0%

Balance sheet

See full
Cash & equivalents$38.8M+98.4%
Total debt$30.1M+1.8%
Total equity$176.0M+19.1%
Total assets$221.6M+17.1%

Cash flow

See full
Operating cash flow-$33.0M-21.5%
CapEx$54.0K+1,700%
Free cash flow-$33.1M-21.7%

Valuation

See full
Market cap$1.19B+236%
Enterprise value$1.19B+224%
P/S4,648.7×

Profitability

See full
Operating margin-19,183.3%
Net margin-19,305.1%
FCF margin-15,518.7%

Returns & leverage

See full
Return on equity-80%+4.7pp
Debt / equity0.2×0.0×
Current ratio13.5×-1.4×

Where this comes from

Calculated from Savara’s reported figures.

Based on the most recent quarter.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Savara's debt-to-assets?
Savara (SVRA) reported debt-to-assets of 0.1× in Q1 2026.
How has Savara's debt-to-assets changed year-over-year?
Savara's debt-to-assets decreased by 13.0% year-over-year, from 0.2× to 0.1×.
What is the long-term trend for Savara's debt-to-assets?
Over 5 years (2020 to 2025), Savara's debt-to-assets has grown at a -14.5% compound annual growth rate (CAGR), from 0.3× to 0.1×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.